Equitable global access to precision cancer diagnostics holds the potential to better inform personalized cancer care.

“The PCC stands to unite global industry leaders through collaborative action to ensure that precision oncology and biomarker-informed, data-driven patient identification are integrated into routine care and clinical research.

Advances in comprehensive genomic profiling (CGP) and liquid biopsy (LBx) have become essential for identifying mutations, tracking cancer progression, and matching patients with clinical trials.

Despite progress, disparities in access persist across geographies, institutions, and patient populations. The PCC’s mission is to close these gaps, ensuring all patients, regardless of location or background, receive appropriate testing.

The PCC envisions a future where every cancer patient worldwide can benefit from precision oncology diagnostics, thanks to collaborative action among industry leaders, laboratories, policymakers, and innovators.

Now is the time to work together to make comprehensive biomarker testing accessible to all cancer patients.”

If you would like to join the PCC, click through to the Membership Enquiries page for more information.

Click on the image or button to download the annual report.